| Why test
with CancerSafe® MARKERS |
| In order to cover a large
range of cancers,the CancerSafe test incorporates the
main tumor markers that are available worldwide. Utilization
of materials and reagents from experts Roche-Boehringer
and Abbott laboratories, this test can look for breast,
ovarian, lung, uterine, prostate, testicle, colorectal,
pancreas, liver, stomach, and thyroid cancers. Order
Online |
| The
Pathologies and their tumor markers |
Breast
Ovary
Uterine
Prostate
Testicle
Colorectal
Pancreas
Liver
Stomach
Esophagus
Thyroid
Lung
Bladder
|
CA-15-3; CEA; CYFRA 21-1
CEA; CA 125; CA 19-9; AFP; BHCG
SCC; CYFRA 21-1; CEA; CA 19-9; CA 125
PSA; FPSA and ratio
BHCG; AFP
CEA; CA 19-9; CA 125
CEA, CA 19-9; CA 72-4
AFP; CEA
CA 72-4; CEA; CA 19-9
CEA; CYFRA 21-1
CEA; NSE
NSE; CYFRA 21-1; CEA; CA 125; CA 19-9
TPA; CEA; CYFRA 21-1
|
|
Tumor
Marker
CEA ng/ml
AFP ng/ml
PSA ng/ml
FPSA/PSA ratio
CA 15-3 U/ml
CA 19-9 U/ml
CA 125 U/ml
CA 72-4 U/ml
BHCG mUI/ml
B2M mg/l
NSE ng/ml
CYFRA 21 ng/ml
|
Ref.Range
<5
<15
<4
>0.25
<40
<35
<35
<5
<5
<2
<15
<3.5
|
Moderate
5-10
15-200
4-10
0.25-0.10
40-60
35-100
35-50
6-30
5-10
2-10
15-40
3.5-5
|
High
>10
>200
>10
<0.10
>60
>100
>50
>30
>10
>10
>40
>5
|
The
panel for women
CEA
CA 15-3
CA 19-9
CA 125
CA 72-4
AFP
BHCG
B2M
NSE
CYFRA 21-1
|
The
panel for men
CEA
CA 19-9
CA 125
CA 72-4
PSA + FPSA with ratio
AFP
BHCG
B2M
NSE
CYFRA 21-1
|
| BENIGN
CONDITIONS |
CEA:
slight to moderate CEA elevations (rarely above 10 ng/ml)
occur in 15-30% of benign diseases of the intestine, the
pancreas, the liver and the lungs: liver cirrhosis, chronic
hepatitis, pancreatitis, ulcerative colitis, Crohn's disease,
and emphysema. Smokers also have elevated CEA values.
CA
15-3:
slightly elevated CA 15-3 serum values (up to 50 U/ml)
are occasionally found in patients with liver cirrhosis,
hepatitis, autoimmune disorders, and benign diseases of
the ovary and breast. Non-mammary malignancies in which
elevated CA 15-3 assay values have been reported include
lung, colon, pancreatic, primary liver, ovarian, cervical,
and endometrial.
CA
19-9:
even slight cholestasis can lead to clearly elevated CA
19-9 serum levels in some cases. Elevated values are also
found with a number of benign and inflammatory diseases
of the gastrointestinal tract and the liver, as well as
in cystic fibrosis.
CA
125:
slight to moderate elevations have been reported in individuals
with non-malignant conditions such as cirrhosis, hepatitis,
endometriosis, first trimester pregnancy, ovarian cysts,
and pelvic inflammatory disease. Elevations during the
menstrual cycle have also been mentioned. Non-ovarian
malignancies include cervical, liver, pancreatic, lung,
colon, stomach, biliary tract, uterine, fallopian tube,
breast and endometrial carcinomas.
CA
72-4:
elevated serum values can be found in benign illnesses:
pancreatitis, cirrhosis of the liver, pulmonary diseases,
rheumatic illnesses, gynecological illnesses, benign diseases
of the ovaries, ovarian cysts, illnesses of the breast,
benign disorders of the gastrointestinal tract.
AFP:
as the AFP values rise during regeneration of the liver,
moderately elevated values are found in alcohol-mediated
liver cirrhosis and acute viral hepatitis, as well as
in carriers of HbsAg (hepatitis B antigen).
PSA:
an inflammation or trauma of the prostate (e.g. in cases
of urinary retention, or following rectal examination,
cystoscopy, colonoscopy, transurethral biopsy, laser treatment
or ergometry) can lead to PSA elevations of varying
duration and magnitude. Benign hypertrophy of the prostate
is frequently involved: the free PSA dosage helps to clear
the matter, with the evaluation of FPSA/PSA quotient.
Free
PSA:
in patients receiving therapy, particularly hormone withdrawal
therapy, the FPSA/PSA quotient cannot be utilized to differentiate
prostate hyperplasia from cancer of the prostate.
B2M:
rheumatic arthritis, lupus, Crohn's disease, myeloma,
chronic lymphoid leukemia can increase results, as does
renal failure.
BHCG:
elevated HCG concentrations not associated with pregnancy
are found in patients with tumors of the germ cells, ovaries,
bladder, pancreas, stomach, lungs and liver.
NSE:
NSE concentrations (inf 12 ng/ml) have been found in patients
with benign pulmonary diseases and cerebral diseases.
Moderate elevations are reported in cerebrovascular meningitis,
disseminated encephalitis, spinocerebellar
degeneration, cerebral ischemia and infarction, intracerebral
hematoma, head injuries, inflammatory brain diseases,
organic epilepsy, schizophrenia, and Jakob-Creutzfeld
disease.
CYFRA:
slightly elevated values (up to 10 ng/ml) are rarely found
in marked benign liver diseases and renal failure. |
| Who
should perform the test? |
| Everyone over 50 should perform it once
a year, or more if required, building your baseline and
data for the future, as years pass your report will include
graphs, demonstrating the evolution of the markers to
assist in treatment and prognosis. |
| What
is the Cost? |
| The cost of the entire panel
is $650, which includes blood draw, Comprehensive Metabolic
Panel, and shipping of your specimen to the laboratory
that processes the CancerSafe tests. If positive results
are indicated, you will receive a follow-up test at no
cost. |
| Results
Example |
| MARKER |
RESULT |
REFERENCE RANGE |
| CA 15-3 |
15.5 U/ml |
‹
40.0 |
| CA
19-9 |
12.7 U/ml |
‹
35.0 |
| CA 125 |
32.0
U/ml |
‹
35.0 |
| CA 72-4 |
0.8
U/ml |
‹
5.2 |
| AFP
|
1.7 ng/ml |
‹
15.0 |
| BHCG |
1.0
mUI/ml |
‹
5 |
| B-2Microglobulin |
1.30
mg/l |
‹
2.0 |
| NSE |
6.5
ng/ml |
‹
15.0 |
| CYFRA 21-1 |
0.7
U/ml |
‹
3.3 |
| CEA |
0.4
ng/ml |
‹
5.0 |
|
| Disclaimer
|
| The CancerSafe® blood test is a screening for evidence
of cancer in the bloodstream. By participating in this
screening exam, you acknowledge that it is a prevention
exam, the result of which does not in any way constitute
a medical diagnosis. It is understood that this test is
NOT a replacement for routinely recommended screening
tests, including, but not limited to, mammography, colonoscopy/fecal
blood testing, PAP smear/bimanual pelvic exam, or any
physical exam. It is understood that a positive test result
or results should be discussed with your physician as
soon as possible, because this may be an indication of
an underlying cancer. Positive results may occur with
benign conditions, also, at times and further evaluation
by a physician would be necessary to determine the significance
of a positive result(s). A negative result does not in
any circumstance mean that there is no cancer present,
just that it is not indicated by the Cancersafe testing
at this time. If any warning signs of cancer are present,
including, but not limited to the signs/symptoms listed
below, you understand that consultation with a physician
immediately is necessary and that the CancerSafe testing
would not take the place of such consultation |
| Testimonial |
"Thank
you DLS for saving my life. I took advantage of your valuable
program and learned that I had prostate cancer.
I am now cancer free
and owe my life to early detection."
Tommy Wells, retired
employee of the La.
Dept. of Insurance |
|
